Role of rifampicin in limiting Escherichia coli O157:H7 Shiga-like toxin expression and enhancement of survival of infected BALB/c mice

International Journal of Antimicrobial Agents

Volumn 37, Issue 2, 2011, Pages 135-139

  Rahal, Elias A ^a   Kazzi, Natalie ^a   Kanbar, Ali ^a   Abdelnoor, Alexander M ^a   Matar, Ghassan M ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Escherichia coli O157:H7; Rifampicin; Shiga like toxins

Indexed keywords

RIFAMPICIN; VEROTOXIN 1; VEROTOXIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG MECHANISM; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LATEX AGGLUTINATION TEST; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRANSCRIPTION TERMINATION; WEIGHT REDUCTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; GENE EXPRESSION; LATEX FIXATION TESTS; MALE; MICE; MICE, INBRED BALB C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIFAMPIN; RNA, MESSENGER; SHIGA TOXINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78751591319     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.10.009     Document Type: Article

References (35)

1. M.A. Elliott, and W.L. Nichols Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome Mayo Clin Proc 76 2001 1154 1162
2. A.X. Garg, R.S. Suri, N. Barrowman, F. Rehman, D. Matsell, and M.P. Rosas-Arellano Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression JAMA 290 2003 1360 1370
3. J. Scheiring, S.P. Andreoli, and L.B. Zimmerhackl Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS) Pediatr Nephrol 23 2008 1749 1760
4. M.A. Karmali, M. Petric, C. Lim, P.C. Fleming, G.S. Arbus, and H. Lior The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli J Infect Dis 151 1985 775 782
5. M. Louie, J. de Azavedo, R. Clarke, A. Borczyk, H. Lior, and M. Richter Sequence heterogeneity of the eae gene and detection of verotoxin-producing Escherichia coli using serotype-specific primers Epidemiol Infect 112 1994 449 461
6. C. Su, and L.J. Brandt Escherichia coli O157:H7 infection in humans Ann Intern Med 123 1995 698 714
7. T.G. Boyce, D.L. Swerdlow, and P.M. Griffin Escherichia coli O157:H7 and the hemolytic-uremic syndrome N Engl J Med 333 1995 364 368
8. G. Reiss, P. Kunz, D. Koin, and E.B. Keeffe Escherichia coli O157:H7 infection in nursing homes: review of literature and report of recent outbreak J Am Geriatr Soc 54 2006 680 684
9. A. Serna, and E.C. Boedeker Pathogenesis and treatment of Shiga toxin-producing Escherichia coli infections Curr Opin Gastroenterol 24 2008 38 47
10. K. Igarashi, T. Ogasawara, K. Ito, T. Yutsudo, and Y. Takeda Inhibition of elongation factor 1-dependent aminoacyl-tRNA binding to ribosomes by Shiga-like toxin I (VT1) from Escherichia coli O157:H7 and by Shiga toxin FEMS Microbiol Lett 44 1987 91 94
11. Y. Endo, K. Tsurugi, T. Yutsudo, Y. Takeda, T. Ogasawara, and K. Igarashi Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes, RNA N-glycosidase activity of the toxins Eur J Biochem 171 1988 45 50
12. T. Ogasawara, K. Ito, K. Igarashi, T. Yutsudo, N. Nakabayashi, and Y. Takeda Inhibition of protein synthesis by a Vero toxin (VT2 or Shiga-like toxin II) produced by Escherichia coli O157:H7 at the level of elongation factor 1-dependent aminoacyl-tRNA binding to ribosomes Microb Pathog 4 1988 127 135
13. P.S. Mead, and P.M. Griffin Escherichia coli O157:H7 Lancet 352 1998 1207 1212
14. A.D. O'Brien, and R.K. Holmes Shiga and Shiga-like toxins Microbiol Rev 51 1987 206 220
15. K.E. Meyers, and B.S. Kaplan Many cell types are Shiga toxin targets Kidney Int 57 2000 2650 2651
16. J. Caprioli, L. Peng, and G. Remuzzi The hemolytic uremic syndromes Curr Opin Crit Care 11 2005 487 492
17. X. Zhang, A.D. McDaniel, L.E. Wolf, G.T. Keusch, M.K. Waldor, and D.W. Acheson Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice J Infect Dis 181 2000 664 670
18. S.M. Qadri, and S. Kayali Enterohemorrhagic Escherichia coli. A dangerous food-borne pathogen Postgrad Med 103 1998 185 187
19. N. Safdar, A. Said, R.E. Gangnon, and D.G. Maki Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis JAMA 288 2002 996 1001 (Pubitemid 34920465)
20. S. Dundas, W.T. Todd, M.A. Neill, and P.I. Tarr Using antibiotics in suspected haemolytic-uraemic syndrome: antibiotics should not be used in Escherichia coli O157:H7 infection BMJ 330 2005 1209 [author reply 1209]
21. P.T. Kimmitt, C.R. Harwood, and M.R. Barer Toxin gene expression by Shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response Emerg Infect Dis 6 2000 458 465
22. G.M. Matar, and E. Rahal Inhibition of the transcription of the Escherichia coli O157:H7 genes coding for Shiga-like toxins and intimin, and its potential use in the treatment of human infection with the bacterium Ann Trop Med Parasitol 97 2003 281 287 (Pubitemid 36606360)
23. Clinical Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 7th ed. 2006 CLSI Wayne, PA [Document M7-A7]
24. O. Olsvik, E. Rimstad, E. Hornes, N. Strockbine, Y. Wasteson, and A. Lund A nested PCR followed by magnetic separation of amplified fragments for detection of Escherichia coli Shiga-like toxin genes Mol Cell Probes 5 1991 429 435
25. A. Nowotny Determination of toxicity Basic exercises in immunochemistry: a laboratory manual 1979 Springer-Verlag Berlin, Germany
26. H. Karch, T. Meyer, H. Russmann, and J. Heesemann Frequent loss of Shiga-like toxin genes in clinical isolates of Escherichia coli upon subcultivation Infect Immun 60 1992 3464 3467
27. G.Z. Panos, G.I. Betsi, and M.E. Falagas Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther 24 2006 731 742
28. A. Rajkovic, N. Smigic, and F. Devlieghere Contemporary strategies in combating microbial contamination in food chain Int J Food Microbiol 141 Suppl 1 2010 S29 42
29. K. Yoshimura, T. Matsui, and K. Itoh Prevention of Escherichia coli O157:H7 infection in gnotobiotic mice associated with Bifidobacterium strains Antonie Van Leeuwenhoek 97 2010 107 117
30. Q. Shu, and H.S. Gill A dietary probiotic (Bifidobacterium lactis HN019) reduces the severity of Escherichia coli O157:H7 infection in mice Med Microbiol Immunol 189 2001 147 152
31. M. Gagnon, E.E. Kheadr, N. Dabour, D. Richard, and I. Fliss Effect of Bifidobacterium thermacidophilum probiotic feeding on enterohemorrhagic Escherichia coli O157:H7 infection in BALB/c mice Int J Food Microbiol 111 2006 26 33
32. T. Asahara, K. Shimizu, K. Nomoto, T. Hamabata, A. Ozawa, and Y. Takeda Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157:H7 Infect Immun 72 2004 2240 2247
33. K.M. Lee, W.S. Kim, J. Lim, S. Nam, M. Youn, and S.W. Nam Antipathogenic properties of green tea polyphenol epigallocatechin gallate at concentrations below the MIC against enterohemorrhagic Escherichia coli O157:H7 J Food Prot 72 2009 325 331
34. A. Lacombe, V.C. Wu, S. Tyler, and K. Edwards Antimicrobial action of the American cranberry constituents; phenolics, anthocyanins, and organic acids, against Escherichia coli O157:H7 Int J Food Microbiol 139 2010 102 107
35. Q. Zhang, A. Donohue-Rolfe, G. Krautz-Peterson, M. Sevo, N. Parry, and C. Abeijon Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection J Infect Dis 199 2009 486 493